Sophie Carter

The paper uses CRISPR-Cas9 in mice to identify modifier genes that affect the severity of tyrosinemia type 1 by editing enzymes in the tyrosine catabolic pathway.

This paper engineers CRISPR-Cas9 variants from Streptococcus thermophilus to target diverse A-rich PAMs, enabling efficient genome editing in mice.

This paper introduces a marker-free co-selection strategy to enhance gene editing efficiency in human cells using CRISPR-Cas9 and Cpf1 systems.